Belite Bio Completes NDA Submission for Stargardt Disease Drug Tinlarebant

summarizeSummary

Belite Bio announced the completion of its New Drug Application (NDA) submission to the FDA for tinlarebant, a drug for Stargardt disease type 1 (STGD1) with Breakthrough Therapy Designation, marking a significant step towards potential market approval.

check_boxKey Events

• NDA Submission Completed

  Belite Bio has completed the rolling submission of its New Drug Application (NDA) to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1).

• Breakthrough Therapy Designation

  The NDA was submitted under Breakthrough Therapy Designation (BTD), granted due to the high unmet medical need for STGD1, a rare inherited retinal disease with no currently approved treatments.

• Next Steps for FDA Review

  The completed application will undergo a 60-day review period with the FDA. If accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned.

• Phase 3 Trial Success

  The Phase 3 DRAGON trial demonstrated tinlarebant's ability to significantly reduce the growth rate of retinal lesions compared to placebo, supporting its potential as the first approved therapy for STGD1.

auto_awesomeAnalysis

Belite Bio has completed the New Drug Application (NDA) submission to the FDA for tinlarebant, a potential first-in-class treatment for Stargardt disease type 1 (STGD1). This is a critical regulatory milestone, following the initiation of the rolling submission in April 2026. The drug has Breakthrough Therapy Designation, highlighting the significant unmet medical need for STGD1 patients. The FDA will now begin a 60-day review period, after which a PDUFA target action date will be assigned, bringing the company closer to potential market approval and commercialization.